Funds

Newton Biocapital II

Want to know more? Contact us!

Have a great business idea already? Submit your proposal to become a part of our portfolio!

Submit your business proposal

Our ESG Policy

Newton Biocapital is committed to ESG compliance: a selection of Environmental, Social and Corporate Governance principles, which form an inherent part of our investment decisions. The ESG policy is aligned with our mission of value creation for all.

NBC II ESG

Newton Biocapital I

Initiated in 2017
Fund size EUR 114 million

Diverse and balanced portfolio of 14 companies with:

  • 10 European and 4 Japanese companies
  • Company stage ranging from research to preclinical and clinical (at first investment)
  • Investments in a variety of disease areas and technologies

NBC I played a leading role in the creation and funding of 4 university spin-offs: Epics Therapeutics, Neuvasq Biotechnologies, Aboleris Pharma and Chromacure.

We attracted investments from other funds and built strong international investor syndicates.

The growth of our portfolio companies contributed to a substantial regional increase in regional employment, in line with our strategy for impact

STRATEGY

About

We attracted investments from other funds and built strong international investor syndicates.

The growth of our portfolio companies contributed to a substantial regional increase in regional employment, in line with our strategy for impact

About

NBC I ESG Disclosure

Although it was conducted with the same guiding principles, NBC I was established before we implemented our full ESG Policy (NBC I ESG Disclosure).

NBC I ESG

Discover the NBC I portfolio!

Portfolio